Why Halozyme Therapeutics, Inc. (HALO) stock fell 15.7% on Friday, November 6, 2026
Halozyme Therapeutics, Inc. (HALO) closed at $103.63, down 15.72% on Friday, November 6, 2026, on volume of 6,161,167 shares (2.6× its 3-month average); market value about $11.80B.
What happened: primary sources
Events Nexqual found for HALO on Friday, November 6, 2026 or the trading day before (November 5, 2026):
- Nov 5, 2026: Reported Q3 2026 results: adjusted EPS $2.39 vs consensus $2.36 (beat), revenue $493.0M vs consensus $491.6M (beat). Guidance: The company raised its full year 2026 guidance for total revenue to $1.860 billion - $1.925 billion and non-GAAP diluted EPS to $8.75 - $9.05. source
- Nov 6, 2026: Citizens: Target raised, Market Outperform, price target $93 → $149
- Nov 6, 2026: Evercore ISI Group: Target raised, Outperform, price target $123 → $125
- Nov 6, 2026: Wells Fargo: Target raised, Equal-Weight, price target $95 → $110
These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.
More on HALO
HALO stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Earnings report: HALO results, November 5, 2026. Other big moves that day: November 6, 2026.
Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 10, 2026 at 16:31 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:31 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt